Friday, July 12, 2024

Netherlands’ analysis ‘recipe’ makes it a hub for European medical trials – report –

A brand new report on the Netherlands’ attractiveness as a vacation spot for medical analysis discovered that the nation is excelling in a number of key areas, together with entry to healthcare, analysis output and specialist areas.

In comparison with different nations, the Netherlands is especially sturdy at early-phase trials – although some facets may have enchancment. Euractiv spoke with the chair of the Dutch Medical Analysis Basis to find out about the important thing components for this success.

The Netherlands excels in a number of key areas, together with simple affected person entry to healthcare and a excessive scientific analysis output providing a selected enchantment in paediatric oncology and Superior Remedy Medicinal Product (ATMP) analysis. These components are contributing to establishing the nation as a prime vacation spot for medical analysis, in response to a brand new report.

The report by Citeline Customized Intelligence, on behalf of a gaggle of private and non-private organisations, discovered that the Netherlands leads in medical analysis on account of its environment friendly trial logistics, sturdy oncology efficiency, Innovation Chief standing, fast ATMP approvals, and sturdy infrastructure.

Nevertheless, it additionally emerged that it’s an costly nation to host trials in and that its small inhabitants measurement means it’s an inappropriate location for single-country trials.

Aiming to be a guiding nation

Reacting to the report, the chairperson of the Dutch Medical Analysis Basis (DCRF), Bart Scheerder, informed Euractiv that they’re proud of the outcomes however that additionally they need to be life like.

“We’re a chief in medical analysis. Not the chief in medical analysis,” he stated, including that the final intention is to maintain enhancing whereas additionally appearing as a guiding nation for others in Europe for the reason that Netherlands nonetheless tremendously values collaboration.

The Citeline report discovered that smaller nations outperform bigger ones in medical trials per capita, with the Netherlands initiating 2.9 occasions extra trials per capita than Germany. Scheerder highlighted a latest article printed by Nature Drugs on the 11 medical trials that can form medication in 2024. Of those, three are carefully linked to the Netherlands.

Seven of 24 ERNs led by Dutch investigators

Scheerder additionally stated the Netherlands punches above its weight in its participation in European Reference Networks (ERNs) – digital networks involving healthcare suppliers throughout Europe that intention to facilitate dialogue on advanced or uncommon ailments. At present 24 ERNs are engaged on a spread of thematic points.

“The Netherlands participates in all of them. And also you may assume, nicely, each nation does, however that’s not the case in any respect.  Extra importantly, seven out of 24 are led by an investigator from the Netherlands,” Scheerder stated.

Scheerder stated the nation pays shut consideration to early-stage medical research with a devoted ethics committee that’s well-organised and speeds issues alongside.

“It’s not that they approve issues that shouldn’t be accredited. However they’re actually skilled and well-organised. Not all are as nicely organised, and oftentimes, folks have to do that on the aspect,” stated Scheerder.

The Netherlands was discovered to have aggressive medical trial start-up occasions, with the time between the trial utility and the primary affected person dosed akin to Germany and the UK. It additionally stands out in approvals for ATMP trials, one in all simply two nations to perform this in beneath 30 days, alongside the UK.

One other benefit the Netherlands provides is its English proficiency.

“You may assume that within the medical trials area, all people speaks English, proper? However that’s not likely the case. Key opinion leaders and important investigators will communicate English. However as for the precise execution of a medical trial in a Dutch hospital you’ll discover that each one the employees that might be concerned do communicate English – from the analysis nurse to the legal professionals to the folks on the ethics board,” stated Scheerder.

‘The liberty to publish is non-negotiable’

The Citeline report additionally beneficial that the Netherlands ought to promote enhanced collaboration between educational hospitals and trade sponsors by addressing institutional boundaries and fostering dialogue by means of the institution of a Nationwide Life Science Council.

Requested about how this collaboration works in follow, Scheerder informed Euractiv that he’s concerned in plenty of public-private partnerships since he works at a college medical centre.

“Typically we do have some friction as a result of the pursuits of a industrial entity generally don’t align nicely with our educational freedom. There are issues we will negotiate such because the variety of days we’ll give the trade to assessment the papers we’re going to publish. However our freedom to publish is non-negotiable,” he stated.

The report by Citeline Customized Intelligence was commissioned by a variety of organisations together with the DCRF and the Dutch Affiliation of Revolutionary Medicines (VIG). The latter can be a member of EFPIA.

[By Christoph Schwaiger, Edited by Vasiliki Angouridi |]

Learn extra with Euractiv

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles